1. Home
  2. ATON vs NLSP Comparison

ATON vs NLSP Comparison

Compare ATON & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATON
  • NLSP
  • Stock Information
  • Founded
  • ATON 1973
  • NLSP 2015
  • Country
  • ATON British Virgin Islands
  • NLSP Switzerland
  • Employees
  • ATON N/A
  • NLSP N/A
  • Industry
  • ATON Oil & Gas Production
  • NLSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATON Energy
  • NLSP Health Care
  • Exchange
  • ATON Nasdaq
  • NLSP Nasdaq
  • Market Cap
  • ATON 13.4M
  • NLSP 12.4M
  • IPO Year
  • ATON N/A
  • NLSP 2021
  • Fundamental
  • Price
  • ATON $6.15
  • NLSP $2.05
  • Analyst Decision
  • ATON
  • NLSP
  • Analyst Count
  • ATON 0
  • NLSP 0
  • Target Price
  • ATON N/A
  • NLSP N/A
  • AVG Volume (30 Days)
  • ATON 98.3K
  • NLSP 206.2K
  • Earning Date
  • ATON 09-30-2025
  • NLSP 10-17-2025
  • Dividend Yield
  • ATON N/A
  • NLSP N/A
  • EPS Growth
  • ATON N/A
  • NLSP N/A
  • EPS
  • ATON N/A
  • NLSP N/A
  • Revenue
  • ATON N/A
  • NLSP N/A
  • Revenue This Year
  • ATON N/A
  • NLSP N/A
  • Revenue Next Year
  • ATON N/A
  • NLSP N/A
  • P/E Ratio
  • ATON N/A
  • NLSP N/A
  • Revenue Growth
  • ATON N/A
  • NLSP N/A
  • 52 Week Low
  • ATON $2.95
  • NLSP $1.30
  • 52 Week High
  • ATON $15.82
  • NLSP $6.97
  • Technical
  • Relative Strength Index (RSI)
  • ATON N/A
  • NLSP 46.22
  • Support Level
  • ATON N/A
  • NLSP $1.80
  • Resistance Level
  • ATON N/A
  • NLSP $2.29
  • Average True Range (ATR)
  • ATON 0.00
  • NLSP 0.14
  • MACD
  • ATON 0.00
  • NLSP -0.00
  • Stochastic Oscillator
  • ATON 0.00
  • NLSP 57.73

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Share on Social Networks: